MedTrace Logo

Anticoagulants for PFO Patients

NCT06375070 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 277

Last updated 2024-04-19

No results posted yet for this study

Summary

Patients who underwent both bubble transcranial Doppler (bubble-TCD) and transoesophageal echocardiography (TEE) at our institution were consecutively enrolled in this real-world case-control study from August 2016 through August 2023. The patients were categorized into three groups based on the degree of the shunt observed: mild (3-9 bubbles), moderate (10-30bubbles), and severe (more than 30 bubbles). In cases with mild-shunt (small-size) PFO, post-procedural anticoagulation or PFO closure was administered. Subsequent to the interventions, the follow-up encompassed the recording of migraine remission, recurrent neurological incidents, instances of major bleeding, and mortality.

Conditions

  • Patent Foramen Ovale

Interventions

PROCEDURE

PFO closure

PFO closure

DRUG

anticoagulant

rivaroxaban

Sponsors & Collaborators

  • Xuanwu Hospital, Beijing

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2022-08-31
Completion
2022-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06375070 on ClinicalTrials.gov